- Home
- PDSB vs IMMX Comparison
PDSB vs IMMX Comparison
Compare PDSB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- IMMX
- Stock Information
- Founded
- PDSB 2005
- IMMX 2014
- Country
- PDSB United States
- IMMX United States
- Employees
- PDSB N/A
- IMMX N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- PDSB Health Care
- IMMX Health Care
- Exchange
- PDSB Nasdaq
- IMMX Nasdaq
- Market Cap
- PDSB 72.2M
- IMMX 65.5M
- IPO Year
- PDSB N/A
- IMMX 2021
- Fundamental
- Price
- PDSB $1.24
- IMMX $2.22
- Analyst Decision
- PDSB Strong Buy
- IMMX Strong Buy
- Analyst Count
- PDSB 2
- IMMX 1
- Target Price
- PDSB $10.00
- IMMX $7.00
- AVG Volume (30 Days)
- PDSB 544.8K
- IMMX 270.4K
- Earning Date
- PDSB 08-13-2025
- IMMX 08-08-2025
- Dividend Yield
- PDSB N/A
- IMMX N/A
- EPS Growth
- PDSB N/A
- IMMX N/A
- EPS
- PDSB N/A
- IMMX N/A
- Revenue
- PDSB N/A
- IMMX N/A
- Revenue This Year
- PDSB N/A
- IMMX N/A
- Revenue Next Year
- PDSB N/A
- IMMX N/A
- P/E Ratio
- PDSB N/A
- IMMX N/A
- Revenue Growth
- PDSB N/A
- IMMX N/A
- 52 Week Low
- PDSB $0.85
- IMMX $1.26
- 52 Week High
- PDSB $4.29
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- PDSB 52.76
- IMMX 45.50
- Support Level
- PDSB $1.15
- IMMX $1.96
- Resistance Level
- PDSB $1.47
- IMMX $2.35
- Average True Range (ATR)
- PDSB 0.10
- IMMX 0.17
- MACD
- PDSB 0.02
- IMMX -0.00
- Stochastic Oscillator
- PDSB 41.03
- IMMX 48.15
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.